SRR23036898
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.380
- INTERFERON_ALPHA_RESPONSE+0.370
- ANDROGEN_RESPONSE+0.350
- APICAL_SURFACE+0.350
- TNFA_SIGNALING_VIA_NFKB+0.330
- PROTEIN_SECRETION+0.300
- TGF_BETA_SIGNALING+0.300
- INTERFERON_GAMMA_RESPONSE+0.260
- ADIPOGENESIS+0.240
- UV_RESPONSE_DN+0.240
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- MYC_TARGETS_V1-0.520
- E2F_TARGETS-0.510
- G2M_CHECKPOINT-0.430
- DNA_REPAIR-0.310
- MTORC1_SIGNALING-0.300
- SPERMATOGENESIS-0.270
- WNT_BETA_CATENIN_SIGNALING-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.170
- OXIDATIVE_PHOSPHORYLATION-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0429cf04-6e5c-41dd-b4a9-4f7ad15d15bc | — | — | 0.873 |
| 2 | SRR17866835 | — | — | 0.849 |
| 3 | SRR12475121 | — | — | 0.836 |
| 4 | SRR12475139 | — | — | 0.834 |
| 5 | TCGA-55-7284-01B-11R-2241-07 | — | cohortA1 | 0.828 |
| 6 | TCGA-78-7540-01A-11R-2066-07 | — | cohortA1 | 0.820 |
| 7 | TCGA-05-4433-01A-22R-1858-07 | — | cohortA1 | 0.812 |
| 8 | SRR12475109 | — | — | 0.804 |
| 9 | TCGA-69-8254-01A-11R-2287-07 | — | cohortA1 | 0.801 |
| 10 | BS_CTR5X93B | pilocytic astrocytoma | — | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |